Turner, N., Dent, R. A., O’Shaughnessy, J., Kim, S., Isakoff, S. J., Barrios, C., . . . Oliveira, M. (2022). Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: Primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Research and Treatment, 191(3), 565-576. https://doi.org/10.1007/s10549-021-06450-x
Chicago-Zitierstil (17. Ausg.)Turner, Nicholas, et al. "Ipatasertib Plus Paclitaxel for PIK3CA/AKT1/PTEN-altered Hormone Receptor-positive HER2-negative Advanced Breast Cancer: Primary Results from Cohort B of the IPATunity130 Randomized Phase 3 Trial." Breast Cancer Research and Treatment 191, no. 3 (2022): 565-576. https://doi.org/10.1007/s10549-021-06450-x.
MLA-Zitierstil (9. Ausg.)Turner, Nicholas, et al. "Ipatasertib Plus Paclitaxel for PIK3CA/AKT1/PTEN-altered Hormone Receptor-positive HER2-negative Advanced Breast Cancer: Primary Results from Cohort B of the IPATunity130 Randomized Phase 3 Trial." Breast Cancer Research and Treatment, vol. 191, no. 3, 2022, pp. 565-576, https://doi.org/10.1007/s10549-021-06450-x.